CPDC Announces Appointment of Bruno Paquin as Permanent CEO

March 10, 2021 CPDC

Hamilton, Ontario (March 10, 2021) – The Centre for Probe Development and Commercialization (CPDC) announced that its Board of Directors has appointed Bruno Paquin as Chief Executive Officer (CEO). The CEO appointment has taken effect on March 4, 2021.

Bruno Paquin - Chief Executive Officer

Dr. John Thornback, Chair of the Board of Directors said, “We are pleased to announce that Bruno Paquin has been appointed CEO of CPDC with immediate effect. The Board feels that Bruno has done an excellent job as interim CEO over the past few months and we are looking forward to working with Bruno, and everyone in the CPDC family, our clients and employees, as he leads us through the next phases of development to a successful future.

Dr. Paquin joined CPDC in 2018, where he supported the Centre as Senior Director of Business Development. Prior to joining CPDC, Bruno was VP Business Development at Immuni T from 2011 to 2018, where his role was central to the growth of the company and to building a pipeline of sponsored research programs. Prior to Immuni T, Bruno started as the Head of the Technology Development Unit at Genizon Biosciences to become the Executive Director, Head of Business Development, from 2000 to 2011. Bruno received his PhD in Biochemistry from Université de Montréal. Bruno Paquin said, “I am honoured to be named CPDC’s CEO and thankful to the Chair and all the members of the Board of Directors for their confidence. The CPDC is an exceptional organization transforming patients’ life by fostering the development of revolutionizing drugs. With the support of the leadership team and that of all the employees, I look forward to leading CPDC to its continuing success and shaping its bright future.”

About CPDC
The Centre for Probe Development and Commercialization (CPDC) is a private, not for profit company dedicated to improving patient’s lives by advancing drugs for the diagnosis and treatment of diseases. Created in 2008, with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University and the Ontario Institute for Cancer Research (OICR), CPDC has become a global leader in the discovery, development and commercialization of next generation radiopharmaceuticals. With an established pipeline of products and a robust and reliable manufacturing unit, CPDC supplies innovative diagnostic and therapeutic radiopharmaceuticals that are used daily in Canada and around the world. CPDC currently employs over 110 staff in Hamilton and Toronto. For more information about CPDC, please visit: www.imagingprobes.ca.

More news from CPDC

CPDC Announces First Patient Dosed in a Phase 3 Clinical Trial of a Prostate Cancer Diagnostic Imaging Product, [18F]PSMA-1007

Hamilton, Ontario, February 24, 2021 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that the first patient has been dosed and imaged in a Phase 3 trial for [18F]PSMA-1007. This diagnostic imaging product is a positron-emitting tomography (PET) agent that

CARI Blog #2: Discover the Medical Isotope & Radiopharmaceutical Landscape in Canada

Did you know that Canada has been a global leader in the research, development and production of medical isotopes as well as radiopharmaceuticals for more than 60 years? Many people are unaware of Canadian role in this industry. However, several medical applications that are used widely today stemmed from Canadian nuclear isotope programs where much

POINT Biopharma signs exclusive license agreement with CanProbe for the commercialization of a neuroendocrine tumor treatment

January 12th, 2021 – TORONTO, CANADA – POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced that it has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium – 177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer.

For more information contact us at: